CSL buys flu vaccine maker

CSL is buying Novartis' influenza vaccine business for US$275m. Once it's combined with CSL’s vaccine division, bioCSL, the combined operations will ‘create the number two global player in the US$4 billion global influenza vaccine industry, with manufacturing plants in the US, UK, Germany and Australia, a diversified product portfolio and strong pre-pandemic and pandemic franchises in its major centres of operation.’ Despite sales of US$527m for the year to December 31, Novartis produced an operating loss of US$138m. Restructuring costs are estimated to be around US$100m; however, CSL expects to save up to US$75m a year by cutting duplicated administration and research costs....

CSL is buying Novartis' influenza vaccine business for US$275m. Once it's combined with CSL’s vaccine division, bioCSL, the combined operations will ‘create the number two global player in the US$4 billion global influenza vaccine industry, with manufacturing plants in the US, UK, Germany and Australia, a diversified product portfolio and strong pre-pandemic and pandemic franchises in its major centres of operation.’

{{content.question}}

SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles